-
SHP-2 Phosphatase: A New Pharmacological Target for Parkinson's Disease?
… Each symptom will be scored on a validated severity scale from 0 to 4. SHP-2 expression and ERK phosphorylation in the … dyskinesias. Final Outcome Treatment of cultured neurons from pre-clinical striatum -- a key area for movement …
-
Validation of Cyclophilin D, a Protein Involved in the Mitochondrial Permeability Transition, as a Target for Parkinson's Disease Therapy
… potential which are prominent features in the tissues from patients with PD and promote PTP opening. To … of the MPT. Using cultures of TH+ dopaminergic neurons from wild type (WT) and Cyp-D knockout mice, our initial …
-
Validation of Sirtuin 3 as a Neuroprotective Target in Parkinson’s Disease
… should reveal which groups of PD patients might benefit from enhanced levels of SIRT3. Final Outcome Mitochondria … health in brain regions affected in PD, to prevent cells from dying using a pre-clinical model of PD. We aimed to …
-
Cerebrospinal Fluid Biomarkers of Microtubule-mediated Axonal Transport for Monitoring of Disease Progression and Therapeutic Interventions in Parkinson's Disease
… patients with Parkinson’s disease. Based on what we learn from this initial human proof-of-concept study, we … of labeling. By then isolating these labeled proteins from small samples of CSF and using an ultra-sensitive mass …
-
New Small Molecule Inhibiting Agents of Alpha-Synuclein & Lewy Body Formation as Disease-Modifying Treatments for Parkinson's Disease
… following only three months of peripheral administration.From the design of more than 250 analogs from this original class of compounds, ProteoTech scientists … and specifically inhibit and disrupt alpha-synuclein from clumping and forming aggregates. In this 3.5-year …
-
The ReStore Study
… to positive or negative events. Apathy is different from depression. It is more common and more severe in … mixed apathy/depression (N=13) or pure apathy (N=11) from the UF Movement Disorders Center. In a 2:1 …